Business Context and Reporting Period
Company: PAVmed Inc. (PAVM)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: PAVmed is a multi-product life sciences company focused on commercializing innovative healthcare technologies. Its primary revenue driver is the EsoGuard Esophageal DNA Test, developed by its subsidiary Lucid Diagnostics Inc. (LUCD). The company also operates Veris Health, focusing on oncology partnerships, and utilizes an incubator model (PMX) for other assets.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $0.98 million | $1.99 million |
| Net Loss (Attributable to PAVmed Common Stockholders) | $(10.91) million | $(33.70) million |
| Net Loss Per Share (Basic & Diluted) | $(1.19) | $(3.78) |
| Operating Cash Flow | N/A | $(24.77) million (Used) |
| Cash and Cash Equivalents (End of Period) | $25.50 million | $25.50 million |
| Total Debt (Senior Secured Convertible Notes at Fair Value) | $44.00 million | $44.00 million |
| Working Capital | $(23.18) million | $(23.18) million |
Note: All figures in millions unless otherwise noted. The company reported negative working capital due to the classification of Senior Secured Convertible Notes as current liabilities.
Material Changes vs. Prior Comparable Period
- Revenue Growth: Revenue increased significantly to $1.99 million for the six months ended June 30, 2024, compared to $0.61 million in the prior year period. This 225% increase is primarily driven by higher volume of EsoGuard tests performed in the company's CLIA laboratory.
- Expense Reduction: Operating expenses decreased. Research and Development (R&D) expenses dropped to $3.58 million (six months 2024) from $7.52 million (six months 2023), largely due to reduced clinical trial activities and consulting fees. General and Administrative (G&A) expenses also declined to $13.69 million from $17.06 million, driven by lower stock-based compensation.
- Debt Fair Value Adjustments: The company recognized a $2.73 million expense related to the change in fair value of Senior Secured Convertible Notes for the six months ended June 30, 2024, compared to $1.38 million in the prior year period.
- Debt Extinguishment Losses: Losses on debt extinguishment totaled $1.13 million for the six months ended June 30, 2024, compared to $1.27 million in the prior year, resulting from converting debt principal into common stock.
Guidance, Outlook, Risks, and Unusual Items
Liquidity and Going Concern
Management has raised substantial doubt about the company's ability to continue as a going concern for the 12 months following the issuance of the financial statements. The company relies on obtaining third-party reimbursement for EsoGuard and raising additional capital through equity or debt financings to meet obligations.
Unusual Items
- Deemed Dividend: A $7.50 million deemed dividend was charged to accumulated deficit in March 2024 following the exchange of Lucid Diagnostics Series A and A-1 Preferred Stock for Series B Preferred Stock.
- Debt Modification Expense: A $2.00 million expense was recognized in the first half of 2024 related to a covenant waiver and maturity extension for Senior Secured Convertible Notes.
Risks and Contingencies
- Nasdaq Compliance: The company received notice from Nasdaq regarding non-compliance with the minimum market value of listed securities ($35 million) rule. It has 180 days (until September 3, 2024) to regain compliance or face delisting.
- Debt Covenants: The company was previously non-compliant with financial covenants (Debt to Market Cap Ratio and Market Cap Test) but obtained a waiver through August 31, 2024.
- Regulatory Environment: While the FDA's final rule on Laboratory Developed Tests (LDTs) does not immediately impact EsoGuard (due to prior marketing and NYS CLEP approval), the company faces ongoing regulatory risks.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $25.5 million cash balance against the $24.8 million operating cash burn for the six-month period and upcoming debt obligations.
- Debt Conversion Terms: Review the specific conversion prices and floor prices for the Senior Secured Convertible Notes, as conversions at prices below the floor have resulted in significant extinguishment losses.
- Nasdaq Compliance Strategy: Assess the company's specific plan to regain the $35 million market value of listed securities by September 3, 2024.
- Reimbursement Status: Confirm the status of third-party reimbursement coverage for the EsoGuard test, which is critical for future revenue growth and liquidity.
- Subsidiary Financing: Monitor the capital raising activities of Lucid Diagnostics (Series B and B-1 Preferred Stock offerings) and their impact on the consolidated balance sheet and noncontrolling interests.